Diaryl-B-Lactam Compound and Preparation Method and Pharmaceutical Use Thereof

Patent metadata

Field	Value
Publication number	US-2022251039-A1
Application number	US-202117451021-A
Country	US
Kind code	A1
Filing date	Oct 15, 2021
Priority date	Mar 29, 2016
Publication date	Aug 11, 2022
Grant date	—

Abstract

The present invention relates to the field of synthetic medicinal chemistry and provides a series of novel diaryl-β-lactam compounds having significant anti-tumor activity, and the pharmaceutical use thereof. The present invention also comprises the use of these compounds, pharmaceutical salts, and pharmaceutical composition thereof for preparing a pharmaceutical for the prevention or treatment of tumor-associated disease. The diaryl-β-lactam compounds of the present invention have the following general formula (I).

First claim

We claim:

1 . A series of diaryl-β-lactam compounds of formula I, and the pharmaceutically acceptable salt, hydrate, solvent mixture, or prodrug thereof,

wherein,
R 1 is one or more groups located on the ring selected from the group consisting of substituted or unsubstituted C1-C4 alkoxy, C1-C4 alkyl, halogen, amino, hydroxy, carboxyl, substituted or unsubstituted C2-C10 acyloxy, C2-C10 ester group, methoxyformyl, allyloxy, propargyloxy, sulfonyloxy, alkylamino, amido, sulfonamido, or the combinations of 2-3 identical or different groups;
R 2 is one or more groups located on the ring selected from the group consisting of substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-C6 alkyl, halogen, amino, hydroxy, carboxyl, fluorosulfonyloxy, allyloxy, propargyloxy, C1-C4 alkylamino, C2-C10 ester group, substituted or unsubstituted C1-C6 alkyl-hydroxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heteroaryl, —OTBS, —CH 2 —R, —OR, —O(C═O)R, —O—(SO 2 )—R, —O(PO)—R 2 , —NH(C═O)R, —NH—(SO 2 )—R;
R 3 and R 4 are each independently selected from the group consisting of substituted or unsubstituted C1-C6 alkyl, hydrogen, acyloxy, hydroxy, carboxy, cyclopropyl, amino, substituted or unsubstituted C1-C4 alkylamino, sulfonyloxy, substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C6 alkyl-hydroxy, substituted or unsubstituted aryl, substituted or unsubstituted morpholinyl, —CH 2 —R, —OR, —O(C═O)R, —O—(SO 2 )—R, —O(PO)—R 2 , —NH(C═O)R, —NH—(SO 2 )—R or R 3 and R 4 together form ═CHR, —OC(═O)OCH 2 —, ═O, C3-C6 cycloalkyl, C3-C6 heterocyclic group or substituted or unsubstituted —(CH 2 ) n —, wherein n is selected from 1, 2, 3, 4, 5 or 6;
R 5 and R 6 are each independently H; or R 5 and R 6 together form ═CHR, —OC(═O)OCH 2 —, ═O, or ═S;
wherein R is selected from the group consisting of vinyl, halogen, amino, hydroxy, carboxy, fluorosulfonyloxy, methylsulfonyl (Ms), substituted or unsubstituted C1-C4 alkoxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted C1-C4 alkylamino, substituted or unsubstituted C2-C10 ester group, substituted or unsubstituted C1-C6 alkyl-hydroxy, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-12 membered heteroaryl;
the substitution means that one or more hydrogen atoms on the group are substituted with a substituent selected from the group consisting of C1-C4 alkoxy, C1-C4 alkyl, halogen, C2-C10 acyloxy, C2-C10 ester group, hydroxy, cyclopropyl, vinyl, amino, oxy group (═O), morpholinyl, sulfonyloxy, C1-C6 amido, —NO 2 , —NHBoc, —NHCbz, —NHC(═O)Me, —OBn, —NHBn, —SiMe 3 , unsubstituted phenyl or pyridyl or substituted by 1 to 3 substituents selected from the group consisting of C1-C4 alkoxy, C1-C4 alkyl, halogen or hydroxy.

2 . The compounds of claim 1 , wherein the compounds have the structure of formula I-1:

wherein each group is defined as in claim 1 .

3 . The compounds of claim 1 , wherein the compounds have the structure of formula I-2:

wherein each group is defined as in claim 1 .

4 . The compounds as shown below:

5 . The compounds of claim 1 wherein said compound is selected from the following:

6 . A use of a pharmaceutical composition of claim 1 in the preparation of a pharmaceutical composition for treating or preventing a disease, wherein the disease is selected from the group consisting of mammalian diseases associated with tubulin aggregation and angiogenesis.

7 . The use of claim 6 , wherein the mammalian disease associated with microtubule-associated protein aggregation is tumor.

8 . The use of claim 6 , wherein the tumor is selected from the group consisting of thyroid cancer, head and neck squamous cell carcinoma, cervical cancer, ovarian cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, osteosarcoma, kidney cancer, stomach cancer, lung cancer, liver cancer, melanoma, lymphoma, prostate cancer, bladder cancer, glioma, nasopharyngeal carcinoma, neuroendocrine cancer, undifferentiated carcinoma, interstitial sarcoma, choriocarcinoma, malignant mole, malignant teratoma or benign tumor.

9 . A pharmaceutical composition, comprising: (i) a therapeutically effective amount of formula I compound, or the pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof, and (ii) a pharmaceutically acceptable carrier.

10 . The preparation method of formula I compound, wherein the method comprises the following steps:

in an inert solvent, compound If provide compound Ig;
and optionally:

compound I is prepared with the compound Ig.

11 . A series of diaryl-β-lactam compounds of formula I, and the pharmaceutically acceptable salt, hydrate

Assignees

• Univ Fudan
• Shanghai Inst Organic Chemistry Cas

Inventors

• Wang Yang
• Liu Mingming
• Zhou Pengfei
• Feng Kechang
• Ding Kuiling
• Wang Xiaoming

Classifications

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D205/08 Primary

  with one oxygen atom directly attached in position 2, e.g. beta-lactams · CPC title

• C07D403/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title